After 6 months of treatment, patients in both the SGLT2-i group and the thiazolidinedione one had a significant decrease in hepatic steatosis, appreciated by means of MRI-PDFF, with no difference in the FIB-4 index and type IV collagen between baseline and post-treatment in both groups. Here, SLC5A2 is linked to fatty liver disease.